A61K 33/241
Lead
Official title: Lead; Compounds thereof
A61K33/241 (Lead) appears on 53 US grants and 57 published applications in this corpus.
Search patents in A61K- Granted patents
- 53
- Published applications
- 57
- Assignees
- 27
- Inventors
- 100
- Latest grant
- 10 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 1 | 0 |
| 2005 | 0 | 2 |
| 2006 | 0 | 1 |
| 2007 | 0 | 4 |
| 2008 | 0 | 3 |
| 2009 | 0 | 5 |
| 2010 | 2 | 3 |
| 2011 | 2 | 3 |
| 2012 | 1 | 1 |
| 2013 | 0 | 4 |
| 2014 | 1 | 5 |
| 2015 | 6 | 2 |
| 2016 | 7 | 5 |
| 2017 | 2 | 2 |
| 2018 | 2 | 3 |
| 2019 | 3 | 0 |
| 2020 | 3 | 6 |
| 2021 | 6 | 1 |
| 2022 | 3 | 3 |
| 2023 | 6 | 0 |
| 2024 | 3 | 2 |
| 2025 | 3 | 1 |
| 2026 | 2 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Stable, highly pure L-cysteine compositions for injection and methods of use10 Mar 2026US 12,569,513 B1Exela Pharma Sciences, LLC
- Stable, highly pure L-cysteine compositions for injection and methods of use10 Mar 2026US 12,569,514 B1Exela Pharma Sciences, LLC
- Use of mutant P53 gene targeted lead borate nanoparticles in cancer treatment and production method of these nanoparticles17 Jun 2025US 12,329,777 B2Yeditepe Universitesi
- Acute and chronic mitochondrial electron transport chain dysfunction treatments and graphenic materials for use thereof17 Jun 2025US 12,329,780 B2Baylor College of Medicine
- Stable, highly pure L-cysteine compositions for injection and methods of use7 Jan 2025US 12,186,338 B1Exela Pharma Sciences, LLC
- Latorias Secret10 Jul 2025US 2025/0221958 A1
- Methods for treatment of patients with myelodysplastic syndromes12 Dec 2024US 2024/0408250 A1Actinium Pharmaceuticals, Inc.
- Cellular production of pure iron oxide nanoparticles11 Jul 2024US 2024/0226299 A1Nanobacterie
- Treatment of major depressive disorder by low dose interleukin-217 Nov 2022US 2022/0362341 A1Therapeutic Solutions International, Inc.
- Composition for treatment of burn with scar removal15 Sep 2022US 2022/0288112 A1
Most cited
By later US patents
- Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors75US 8,883,803 B2Pharmacyclics, Inc. · 2014
- Modified vaccinia virus strains for use in diagnostic and therapeutic methods40US 8,052,968 B2Genelux Corporation · 2011
- Inhibitors of Bruton'S tyrosine kinase for the treatment of solid tumors38US 9,107,924 B2Pharmacyclics, Inc. · 2015
- Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors38US 9,278,100 B2Pharmacyclics, Inc. · 2016
- Stable, highly pure L-cysteine compositions for injection and methods of use21US 10,478,453 B1Exela Pharma Sciences, LLC · 2019